1071 related articles for article (PubMed ID: 30292481)
1. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
Jault P; Leclerc T; Jennes S; Pirnay JP; Que YA; Resch G; Rousseau AF; Ravat F; Carsin H; Le Floch R; Schaal JV; Soler C; Fevre C; Arnaud I; Bretaudeau L; Gabard J
Lancet Infect Dis; 2019 Jan; 19(1):35-45. PubMed ID: 30292481
[TBL] [Abstract][Full Text] [Related]
2. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
3. Engineered Superinfective Pf Phage Prevents Dissemination of Pseudomonas aeruginosa in a Mouse Burn Model.
Prokopczuk FI; Im H; Campos-Gomez J; Orihuela CJ; Martínez E
mBio; 2023 Jun; 14(3):e0047223. PubMed ID: 37039641
[TBL] [Abstract][Full Text] [Related]
4. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.
Leitner L; Ujmajuridze A; Chanishvili N; Goderdzishvili M; Chkonia I; Rigvava S; Chkhotua A; Changashvili G; McCallin S; Schneider MP; Liechti MD; Mehnert U; Bachmann LM; Sybesma W; Kessler TM
Lancet Infect Dis; 2021 Mar; 21(3):427-436. PubMed ID: 32949500
[TBL] [Abstract][Full Text] [Related]
5. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
Beigel JH; Aga E; Elie-Turenne MC; Cho J; Tebas P; Clark CL; Metcalf JP; Ozment C; Raviprakash K; Beeler J; Holley HP; Warner S; Chorley C; Lane HC; Hughes MD; Davey RT;
Lancet Respir Med; 2019 Nov; 7(11):941-950. PubMed ID: 31582360
[TBL] [Abstract][Full Text] [Related]
6. Improving the Inhibitory Effect of Phages against
Aghaee BL; Khan Mirzaei M; Alikhani MY; Mojtahedi A; Maurice CF
Viruses; 2021 Feb; 13(2):. PubMed ID: 33670028
[TBL] [Abstract][Full Text] [Related]
7. Design of a Broad-Range Bacteriophage Cocktail That Reduces Pseudomonas aeruginosa Biofilms and Treats Acute Infections in Two Animal Models.
Forti F; Roach DR; Cafora M; Pasini ME; Horner DS; Fiscarelli EV; Rossitto M; Cariani L; Briani F; Debarbieux L; Ghisotti D
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555626
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
9. Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial.
Tamma PD; Souli M; Billard M; Campbell J; Conrad D; Ellison DW; Evans B; Evans SR; Greenwood-Quaintance KE; Filippov AA; Geres HS; Hamasaki T; Komarow L; Nikolich MP; Lodise TP; Nayak SU; Norice-Tra C; Patel R; Pride D; Russell J; Van Tyne D; Chambers HF; FowlerJr VG; Schooley RT;
Trials; 2022 Dec; 23(1):1057. PubMed ID: 36578069
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
11. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
Wright A; Hawkins CH; Anggård EE; Harper DR
Clin Otolaryngol; 2009 Aug; 34(4):349-57. PubMed ID: 19673983
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
13. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.
Vinodkumar CS; Kalsurmath S; Neelagund YF
Indian J Pathol Microbiol; 2008; 51(3):360-6. PubMed ID: 18723958
[TBL] [Abstract][Full Text] [Related]
14. Assessing antibacterial efficacy of a polyhexanide hydrogel versus alginate-based wound dressing in burns.
De Decker I; Janssens D; De Mey K; Hoeksema H; Simaey M; De Coninck P; Verbelen J; De Pessemier A; Blondeel P; Monstrey S; Claes KE
J Wound Care; 2024 May; 33(5):335-347. PubMed ID: 38683776
[TBL] [Abstract][Full Text] [Related]
15. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG; Matsunaga Y; Ariyasu M; Clevenbergh P; Echols R; Kaye KS; Kollef M; Menon A; Pogue JM; Shorr AF; Timsit JF; Zeitlinger M; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):213-225. PubMed ID: 33058798
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
[TBL] [Abstract][Full Text] [Related]
17. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model.
McVay CS; Velásquez M; Fralick JA
Antimicrob Agents Chemother; 2007 Jun; 51(6):1934-8. PubMed ID: 17387151
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.
de Jong E; van Oers JA; Beishuizen A; Vos P; Vermeijden WJ; Haas LE; Loef BG; Dormans T; van Melsen GC; Kluiters YC; Kemperman H; van den Elsen MJ; Schouten JA; Streefkerk JO; Krabbe HG; Kieft H; Kluge GH; van Dam VC; van Pelt J; Bormans L; Otten MB; Reidinga AC; Endeman H; Twisk JW; van de Garde EMW; de Smet AMGA; Kesecioglu J; Girbes AR; Nijsten MW; de Lange DW
Lancet Infect Dis; 2016 Jul; 16(7):819-827. PubMed ID: 26947523
[TBL] [Abstract][Full Text] [Related]
19. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
Carmeli Y; Armstrong J; Laud PJ; Newell P; Stone G; Wardman A; Gasink LB
Lancet Infect Dis; 2016 Jun; 16(6):661-673. PubMed ID: 27107460
[TBL] [Abstract][Full Text] [Related]
20. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA;
Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
